A steady march of investments in U.S. high-technology sectors by Chinese companies from telecom to biotech will come into focus this week in high-level talks in Washington, DC, that will cover a proposed bilateral investment treaty, Reuters reports.
The FDA approved a device that enables blind users to interpret the shape, size, location and motion of objects from patterns of electrical stimulation on the surface of their tongue.
The FDA released an overview of its considerations and process for reviewing so-called investigational device exemptions, which give researchers permission to test developmental devices on humans.
Celgene has high hopes for its anti-inflammatory drug Otezla, shooting for blockbuster sales of the med with the help of new indications for psoriatic arthritis and psoriasis. But the company is off to a rough start with the drug in the U.K., as the country's cost gatekeeper decided not to recommend Otezla to treat psoriatic arthritis.
Japan's National Health Insurance (NHI) has confirmed that a slew of generic versions of Sanofi's Plavix will join the reimbursement list after the latest review, a move tipped by the company in its first-quarter earnings call as well.
The FDA has overhauled its Risk Evaluation and Mitigation Strategies website to make it easier to find up-to-date information. The new version moves details of whether REMS apply to a drug, what components are in place and when they were last updated to the forefront, ending the need for users to dig through a database to find information.
WuXi PharmaTech sought and has been approved for an extension under U.S. Securities and Exchange Commission Rule 406 to keep confidential treatment of information excluded from Form F-1 filed on July 24, 2007, as amended, according to an order filed June 17.
China's Pearl River flows with residues of three dozen types of common antibiotics widely consumed by top-user China, a Chinese Academy of Sciences-sponsored study found. The study suggests that overuse by humans and animals is the main driver causing densely populated areas to see high concentrations of antibiotic residue.
The FDA warned of higher mortality rates among patients on SynCardia Systems' Total Artificial Heart Companion 2 Driver System who underwent certain preimplant interventions.
The FDA has approved the Misago Peripheral Stent System from Terumo to treat peripheral artery disease by restoring blood flow to the leg. Upon the FDA's disclosure Terumo almost immediately said it would launch the device at the ongoing Society for Vascular Surgery Annual Meeting in Chicago, IL.